PI-103

Catalog No.S1038 Batch:S103803

Print

Technical Data

Formula

C19H16N4O3
Molecular Weight 348.36 CAS No. 371935-74-9
Solubility (25°C)* In vitro DMSO 24 mg/mL (68.89 mM)
Water Insoluble
Ethanol Insoluble
In Vivo (Add solvents to the product individually and in order.)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description PI-103 is a multi-targeted PI3K inhibitor for p110α/β/δ/γ with IC50 of 2 nM/3 nM/3 nM/15 nM in cell-free assays, less potent to mTOR/DNA-PK with IC50 of 30 nM/23 nM. This compound induces apoptosis in murine T-cell Lymphoma.
Targets
p110α
(Cell-free assay)		 p110β
(Cell-free assay)		 p110δ
(Cell-free assay)		 p110γ
(Cell-free assay)		 DNA-PK
(Cell-free assay)		 View More
2 nM 3 nM 3 nM 15 nM 23 nM
In vitro

PI-103 potently inhibits both the rapamycin-sensitive (mTORC1) and rapamycin-insensitive (mTORC2) complexes of the protein kinase mTOR. This compound inhibits constitutive and growth factor-induced PI3K/Akt, as well as mTORC1 activation. In blast cells, it inhibits leukemic proliferation, the clonogenicity of leukemic progenitors and induces mitochondrial apoptosis, especially in the compartment containing leukemic stem cells. This chemical inhibits p110α >200-fold more potently than p110β. It also potently blocks production of PI(3,4)P2 and PIP3 in adipocytes and PIP3 in myotubes. This compound inhibits phosphorylation of Akt with an IC95 100-fold lower than that for LY294002. Strikingly, it completely protects animals from stimulated decline in blood glucose. It has additive proapoptotic effects in blast cells and in immature leukemic cells.

In Vivo

When tumours reach 50-100 mm3, animals are randomised and treated with vehicle or PI-103. This compound exhibits significant activity, decreasing average tumour size by 4-fold after 18 days. Mice treated with this chemical have no obvious signs of toxicity premorbidly (based on body weight, food and water intake, activity, and general exam) or at necropsy. Treated tumours display decreased levels of phosphorylated Akt and S6, consistent with blockade of p110α and mTOR. This treatment is cytostatic to glioma xenografts.

Features The first potent, synthetic mTOR inhibitor.

Protocol (from reference)

Kinase Assay:

[3]
  • Enzyme Assays

    Phosphatidylinositide 3-kinase inhibitory activity was determined using a scintillation proximity assay in the presence of 1 μmol/L ATP. Inhibition of mTOR protein kinase was determined using a TR-FRET-based LanthaScreen method from Invitrogen. This compound was assayed at a maximum concentration of 10 μmol/L in the presence of 1 μmol/L ATP, and IC50 values were determined using GraphPad Prism software.
Cell Assay:

[2]
  • Cell Lines

    U87MG cells

  • Concentrations

    0.5 μM

  • Incubation Time

    24 hours

  • Method

    U87MG cells are treated with PI-103 for 24 hours. Cell death is quantified by colorimetric determination of LDH activity using a cytotoxicity detection kit. Percentage of cell death (mean of three 12-well plates per experimental point) is calculated [(experimental value- low control)/(high control -low control) × 100], where the low-control cells are DMSO treated and high-control cells are Triton treated (1% Triton X-100, 30 min, 37 °
Animal Study:

[2]
  • Animal Models

    6- to 12-week-old Balbc nu/nu mice bearing U87MG:ΔEGFR cells

  • Dosages

    5 mg/kg

  • Administration

    Administered via i.p.

References

  • https://pubmed.ncbi.nlm.nih.gov/16647110/
  • https://pubmed.ncbi.nlm.nih.gov/16697955/
  • https://pubmed.ncbi.nlm.nih.gov/19584227/

Customer Product Validation

<p>We treated all of drugs in T47D which has a PI3KCA H1044R mutation with the concentration shown below for 1 hour and performed western blot analysis using antibodies to phospho-AKT(SERINE 472), and total AKT.</p><div><div> </div></div><p> </p>

, Saraswati Sukumar of Johns Hopkins University School of Medicine

<p>Knockdown of BRCA1 sensitizes cells to PI3K/AKT pathway inhibitors. MCF7 cells transfected with either BRCA1-siRNA or control-siRNA were treated with increasing amounts of inhibitors targeting the PI3K/AKT pathway for 48 h in triplicate. Viable cells were measured by MTT assay.</p>

Data from [ Mol Carcinog , 2012 , ahead of print ]

<p>(A) MCF7 cells pre-treated with 100 nM siRNA for 72 h were re-seeded with normal growth media and grown overnight, then further transfected by 100nM of fresh siRNA. Twenty-(A) four hours after transfection, the cells were further treated with PI-103 for 24 h and the cell lysates were immunoblotted with the indicated antibodies. (B) Breast cancer cells carrying BRCA1 mutations were treated with 1 mM of PI-103 for 24h (left) or increasing amounts of PI-103 for 24 h (right). Cell lysates were analyzed by Western blotting with the indicated antibodies.</p>

Data from [ Mol Carcinog , 2012 , 52, 667-75 ]

<p>Breast cancer cells were pretreated with 100ng/ml EGF for 15 min and then treated with the indicated concentrations of PI-103 for 24 hours.</p><div><div> </div></div><p> </p>

, , Dr. Zhang of Tianjin Medical University

Sellecks PI-103 Has Been Cited by 110 Publications

hnRNPL phase separation activates PIK3CB transcription and promotes glycolysis in ovarian cancer [ Nat Commun, 2025, 16(1):4828] PubMed: 40413189
Bile acid-FXR signaling facilitates the long-term maintenance of hepatic characteristics in human iPSC-derived organoids [ Cell Rep, 2025, 44(5):115675] PubMed: 40367952
Autophagy and PXR Crosstalk in the Regulation of Cancer Drug Metabolism and Resistance According to Gene Mutational Status in Colorectal Cancer [ Genes (Basel), 2025, 16(8)892] PubMed: 40869940
Development of Acquired Resistance in Alpelisib-treated Gastric Cancer Cells With PIK3CA Mutations and Overcoming Strategies [ Anticancer Res, 2025, 45(5):1877-1896] PubMed: 40295072
TMEM176B Promotes EMT via FGFR/JNK Signalling in Development and Tumourigenesis of Lung Adenocarcinoma [ Cancers (Basel), 2024, 16(13)2447] PubMed: 39001509
Overcoming brain-derived therapeutic resistance in HER2+ breast cancer brain metastasis [ bioRxiv, 2024, 2024.02.19.581073] PubMed: 38529509
Young and undamaged recombinant albumin alleviates T2DM by improving hepatic glycolysis through EGFR and protecting islet β cells in mice [ J Transl Med, 2023, 21(1):89] PubMed: 36747238
RIDR-PI-103, ROS-activated prodrug PI3K inhibitor inhibits cell growth and impairs the PI3K/Akt pathway in BRAF and MEK inhibitor-resistant BRAF-mutant melanoma cells [ Anticancer Drugs, 2023, 34(4):519-531] PubMed: 36847042
Synergistic effects of complex drug combinations in colorectal cancer cells predicted by logical modelling [ Front Syst Biol, 2023, Volume 3] PubMed: None
Integrative analysis of drug response and clinical outcome in acute myeloid leukemia [ Cancer Cell, 2022, S1535-6108(22)00312-9] PubMed: 35868306

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.